Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR4640 in Hyperuricemia With or Without Gout – Phase II
CTR20170584Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruzinurad in hyperuricemia, gout, sponsored by Hengrui Therapeutics. Started Jun 2017; status: completed.
02
Drugs
ruzinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on CTR20170584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170584.